We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Time-Release Approach for Treating Type II Diabetes

By LabMedica International staff writers
Posted on 13 Jun 2017
Print article
Image: A glucose-controlling drug (blue) is shown completely dissolving after 24 hours in the body of a mouse in the top two photos. In the bottom two images, a newly optimized version of a diabetes treatment forms a \"depot\" for controlled release that persists more than 24 hours (Photo courtesy of Dr. Ashutosh Chilkoti, Duke University).
Image: A glucose-controlling drug (blue) is shown completely dissolving after 24 hours in the body of a mouse in the top two photos. In the bottom two images, a newly optimized version of a diabetes treatment forms a \"depot\" for controlled release that persists more than 24 hours (Photo courtesy of Dr. Ashutosh Chilkoti, Duke University).
A novel approach to treating type II diabetes is based on a timed-release suspension of glucagon-like peptide-1 (GLP1) embedded in a thermosensitive elastin-like polypeptide complex.

Stimulation of the GLP1 receptor (GLP1R) is a useful treatment strategy for type II diabetes. GLP1R is known to be expressed in pancreatic beta cells. Activated GLP1R stimulates the adenylyl cyclase pathway, which results in increased insulin synthesis and release of insulin. Consequently, GLP1R has been a target for developing drugs usually referred to as GLP1R agonists to treat diabetes. GLP1R is also expressed in the brain where it is involved in the control of appetite. However, the native ligand for the GLP1 receptor has a short half-life owing to enzymatic inactivation and rapid clearance.

In order to increase the half-life of GLP1, investigators at Duke University (Durham, NC, USA) developed a method that embedded GLP1 in a heat-sensitive elastin-like polypeptide (ELP) in a solution that could be injected into the skin through a standard needle. Once injected, the solution reacted with body heat to form a biodegradable gel-like deposit that slowly released the drug as it dissolved.

The investigators worked with mouse and monkey diabetes models. They reported in the June 5, 2017, online edition of the journal Nature Biomedical Engineering that a subcutaneous depot formed after a single injection of GLP1 fused to a thermosensitive elastin-like polypeptide and displayed zero-order release kinetics and circulation times of up to 10 days in mice and 17 days in monkeys. The optimized pharmacokinetics led to 10 days of glycemic control in three different mouse models of diabetes, as well as the reduction of glycosylated hemoglobin levels and weight gain in obese mice treated once weekly for eight weeks.

"Although we have pursued this method in the past, a researcher in my lab systematically worked to vary the design of the delivery biopolymer at the molecular level and found a sweet spot that maximized the duration of the drug's delivery from a single injection," said senior author Dr. Ashutosh Chilkoti, professor of biomedical engineering at Duke University. "By doing so, we managed to triple the duration of this short-acting drug for type II diabetes, outperforming other competing designs."

Related Links:
Duke University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.